Original Research

Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds

Wilke T, Picker N, Müller S, Stürmlinger A, Deiters B, Dittmar A, Aberle J, Gabler M

ClinicoEconomics and Outcomes Research 2022, 14:319-332

Published Date: 2 May 2022